Ajanta Pharma (AJANTPHARM) Fundamentals 2026 — P/E 40.9x, Revenue Analysis | SniperIQ
Ajanta Pharma (AJANTPHARM) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹43,189 Crore, trading at ₹3459.25 on the BSE. This SniperIQ fundamentals page covers Ajanta Pharma's valuation (P/E 40.9x, P/B 9.5x), profitability (net margin 19.4%), revenue (₹5,453 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ajanta Pharma's market cap?
Ajanta Pharma (AJANTPHARM) has a market capitalization of approximately ₹43,189 Crore, trading at ₹3459.25 on the BSE. Market cap moves with the live share price.
What is Ajanta Pharma's P/E ratio?
Ajanta Pharma's trailing twelve-month P/E ratio is 40.9x, with a price-to-book (P/B) of 9.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ajanta Pharma?
Ajanta Pharma runs a net profit margin of 19.4%, a gross margin of 71.7%, and an operating margin of 45.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ajanta Pharma generate?
Ajanta Pharma reported revenue of ₹5,453 Crore for fiscal year 2026, with net income of ₹1,056 Crore and earnings per share (EPS) of 84.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ajanta Pharma pay a dividend?
Ajanta Pharma offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Ajanta Pharma financially healthy?
Ajanta Pharma carries a debt-to-equity ratio of 0.06x and a current ratio of 2.64x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ajanta Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ajanta Pharma (AJANTPHARM) the key facts are: market cap ₹43,189 Crore, P/E 40.9x, revenue ₹5,453 Crore, 52-week range 2022.05-3598.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ajanta Pharma's full fundamentals live
Get Ajanta Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.